From a technical perspective, Oscar Health, Inc. (OSCR) is looking like an interesting pick, as it just reached a key level of support. OSCR recently overtook the 20-day moving average, and this suggests a short-term bullish trend.
Oscar Health, Inc. (OSCR) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, OSCR's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
Oscar Health, Inc. (OSCR) Q1 2026 Earnings Call Transcript
Oscar Health (OSCR) delivered a standout Q1 2026, with $4.65B revenue, 52.7% YoY growth, and a 70.5% medical loss ratio. I reaffirm my Strong Buy rating and raise the 2026 price target to $30, citing robust execution and guidance reaffirmation. OSCR's SG&A leverage and technology platform drove operating efficiency, with Q1 Adjusted EBITDA at $727.1M and SG&A ratio likely below 15.8%.
Oscar Health, Inc. (OSCR) came out with quarterly earnings of $2.07 per share, beating the Zacks Consensus Estimate of $1.21 per share. This compares to earnings of $0.92 per share a year ago.
Health insurer Oscar Health swung to a $679 million first quarter profit – the highest in company history – as its health plan membership jumped more than 50% and medical costs eased.
Oscar Health, Inc. (OSCR) closed the most recent trading day at $18.46, moving +2.96% from the previous trading session.
Oscar Health (OSCR) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
In the most recent trading session, Oscar Health, Inc. (OSCR) closed at $16.44, indicating a +1.67% shift from the previous trading day.
In the closing of the recent trading day, Oscar Health, Inc. (OSCR) stood at $16.17, denoting a -1.64% move from the preceding trading day.
In the closing of the recent trading day, Oscar Health, Inc. (OSCR) stood at $15.29, denoting a -1.23% move from the preceding trading day.
Oscar Health remains a "Buy" despite recent underperformance and a 7% stock drop since my last update. Management's 61% growth guidance sets high expectations; meeting it could drive positive price action and multiple expansion. Insider buying by the CEO boosts investor confidence in OSCR's outlook and execution.